Page 1

03 Financial Summary for the group KSEK Profit / loss before tax Total assets Earnings per share before and after dilution ( SEK ) Cash and cash equivalents as per period end Equity ratio as per period end Significant Events Significant events during the third quarter of 2021 Cyxone and Medical University of Vienna announced collaboration to study broader T20K use in MS ● Cyxone recruited Chief Medical Officer and key members to the development team ● Cyxone announced Rabeximod in Covid - 19 Phase 2 trial closed Cyxone to leverage IND and use FDA pre - review for Covid - 19 phase 2 trial ● ● Interim Report Q3 2021 January - September Tara Heitner , CEO Phone : +46 ( 0 ) 70 781 88 08 E - mail : tara.heitner@cyxone.com 2021-07-01 2021-09-30 -10 974 58 567 -0,17 42 963 90,8 % Cyxone AB ( Corp. reg . no . 559020-5471 ) CYXONE 2020-07-01 2020-09-30 -12 620 61 797 -0,26 45 562 91,0 % 2021-01-01 2021-09-30 No significant events -31 043 58 567 -0,51 42 963 90,8 % Significant events after the end of the period Follow our news and information about our presence at investment events via Nasdaq First North Growth Market and the company's website : www.cyxone.com . 2020-01-01 2020-09-30 This is a translation of the original Swedish version of the interim report . In case of any discrepancy between this translation and the Swedish original , the latter shall prevail . The information was submitted for publication , through the agency of the contact person set out above , at 08.30 a.m. CEST on 29th of October 2021 . -37 014 61 797 -0,75 45 562 91,0 % Interim Report Q3 2021 | 1